These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 25381047

  • 1. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
    Kalder M, Kyvernitakis I, Albert US, Baier-Ebert M, Hadji P.
    Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
    [Abstract] [Full Text] [Related]

  • 2. Effects of zoledronate versus placebo on spine bone mineral density and microarchitecture assessed by the trabecular bone score in postmenopausal women with osteoporosis: a three-year study.
    Popp AW, Guler S, Lamy O, Senn C, Buffat H, Perrelet R, Hans D, Lippuner K.
    J Bone Miner Res; 2013 Mar; 28(3):449-54. PubMed ID: 23018784
    [Abstract] [Full Text] [Related]

  • 3. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P, Kauka A, Ziller M, Birkholz K, Baier M, Muth M, Bauer M.
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
    Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
    [Abstract] [Full Text] [Related]

  • 6. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
    Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M.
    Calcif Tissue Int; 2017 Oct; 101(4):396-403. PubMed ID: 28589205
    [Abstract] [Full Text] [Related]

  • 7. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K.
    Osteoporos Int; 2014 Jul; 25(7):1945-51. PubMed ID: 24760244
    [Abstract] [Full Text] [Related]

  • 8. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C, Reid DM, Devogelaer JP, Saag K, Lau CS, Reginster JY, Papanastasiou P, Bucci-Rechtweg C, Su G, Sambrook PN.
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [Abstract] [Full Text] [Related]

  • 9. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR, Lippuner K, Brandi ML, Zanchetta JR, Bone HG, Chapurlat R, Hans D, Wang A, Zapalowski C, Libanati C.
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [Abstract] [Full Text] [Related]

  • 10. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 11. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON.
    Popp AW, Buffat H, Cavelti A, Windolf M, Perrelet R, Senn C, Lippuner K.
    Maturitas; 2014 Mar; 77(3):287-93. PubMed ID: 24485216
    [Abstract] [Full Text] [Related]

  • 12. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
    Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM, HORIZON Pivotal Fracture Trial.
    Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
    [Abstract] [Full Text] [Related]

  • 13. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.
    Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
    [Abstract] [Full Text] [Related]

  • 14. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A, Frassoldati A, Paija O, Sleeboom HP, Jerusalem G, Mebis J, Deleu I, Miller J, Schenk N, Neven P.
    Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer.
    Hershman DL, McMahon DJ, Crew KD, Cremers S, Irani D, Cucchiara G, Brafman L, Shane E.
    J Clin Oncol; 2008 Oct 10; 26(29):4739-45. PubMed ID: 18711172
    [Abstract] [Full Text] [Related]

  • 16. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
    Liang BC, Shi ZY, Wang B, Wu P, Kong LC, Yao JL, Li CW, Shi XL.
    Orthop Surg; 2017 Feb 10; 9(1):103-109. PubMed ID: 28276638
    [Abstract] [Full Text] [Related]

  • 17. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
    Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY.
    Breast Cancer Res Treat; 2011 Jan 10; 125(1):99-106. PubMed ID: 20922564
    [Abstract] [Full Text] [Related]

  • 18. A single dose of intravenous zoledronate prevents glucocorticoid therapy-associated bone loss in acute flare of Crohn's disease, a randomized controlled trial.
    Klaus J, Haenle MM, Schröter C, Adler G, von Boyen G, Reinshagen M, von Tirpitz C.
    Am J Gastroenterol; 2011 Apr 10; 106(4):786-93. PubMed ID: 21386830
    [Abstract] [Full Text] [Related]

  • 19. Once-yearly zoledronic acid in older men compared with women with recent hip fracture.
    Boonen S, Orwoll E, Magaziner J, Colón-Emeric CS, Adachi JD, Bucci-Rechtweg C, Haentjens P, Kaufman JM, Rizzoli R, Vanderschueren D, Claessens F, Sermon A, Witvrouw R, Milisen K, Su G, Lyles KW, HORIZON Recurrent Fracture Trial.
    J Am Geriatr Soc; 2011 Nov 10; 59(11):2084-90. PubMed ID: 22091563
    [Abstract] [Full Text] [Related]

  • 20. The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: a prospective, randomized, phase II trial.
    Safra T, Bernstein-Molho R, Greenberg J, Pelles-Avraham S, Stephansky I, Sarid D, Inbar MJ, Stemmer SM, Geffen DB.
    Oncology; 2011 Nov 10; 81(5-6):298-305. PubMed ID: 22156381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.